Pharming (PHAR) Total Non-Current Liabilities (2019 - 2026)

Pharming's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $108.1 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 2.08% year-over-year to $108.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.1 million (down 2.08% YoY) and the FY2025 annual result came in at $107.1 million, up 1.85% from the prior year.
• Total Non-Current Liabilities was $108.1 million for Q1 2026 at Pharming, up from $107.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $166.1 million in Q4 2023 and bottomed at $135375.0 in Q3 2022.
• A 5-year average of $120.5 million and a median of $119.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 99.92% — and 2023, when it jumped 116957.8%.
• Pharming's Total Non-Current Liabilities stood at $161.5 million in 2022, then grew by 2.88% to $166.1 million in 2023, then plunged by 36.71% to $105.1 million in 2024, then climbed by 1.85% to $107.1 million in 2025, then increased by 0.92% to $108.1 million in 2026.
• Business Quant data shows PHAR's Total Non-Current Liabilities at $108.1 million in Q1 2026, $107.1 million in Q4 2025, and $121.2 million in Q3 2025.